Investment supports phase IIb clinical trial examining novel PTSD treatmentTORONTO, ON / ACCESSWIRE / April 13, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pl...Read More
Toronto, Ontario--(Newsfile Corp. - March 24, 2021) - Novamind Inc. (CSE: NM) (OTC Pink: NVMDF) (FSE: HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Benzinga Biotech Small Cap Conference ("the...Read More
Panel discussion on psychedelic treatments and therapies to feature Novamind's Chief Medical OfficerTORONTO, ON / ACCESSWIRE / March 22, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized i...Read More
Novamind's subsidiary, Cedar Clinical Research, to serve as a key clinical research siteTORONTO, ON / ACCESSWIRE / March 18, 2021 / Novamind Inc., (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedel...Read More
VANCOUVER, BC, March 18, 2021 /CNW/ - Trading resumes in: Company: Novamind Inc. CSE Symbol: NM All Issues: Yes Resumption (ET): 9:30 AM IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensur...Read More
VANCOUVER, BC, March 16, 2021 /CNW/ - The following issues have been halted by IIROC: Company: Novamind Inc. CSE Symbol: NM All Issues: Yes Reason: At the request of the Company Pending News Halt Time (ET): 3:02 PM IIROC can make a decision to impose a temporary suspension (halt) of trading in a...Read More
Joseph Braganza joins the organization as SVP, Head of M&APreviously led M&A at Canadian Addiction Treatment Centres (CATC)TORONTO, ON / ACCESSWIRE / March 3, 2021 / Novamind Inc., (CSE:NM)(OTC PINK:NVMDF) ("Novamind" or the "Company"), a leading mental health com...Read More
$1.29 million in fiscal second quarter revenueClinics see continued surge in demand for mental health servicesOngoing expansion of clinic capacityTORONTO, ON / ACCESSWIRE / March 1, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF) ("Novamind" or "the Company"), a leading men...Read More
Toronto, Ontario--(Newsfile Corp. - February 24, 2021) - Novamind Inc. (CSE: NM) (OTC Pink: NVMDF) ("Novamind" or "the Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Benzinga Cannabis Capital Conference ("the Conference...Read More
Psychedelics panel discussion to feature Novamind's Chief Medical OfficerTORONTO, ON / ACCESSWIRE / February 23, 2021 / Novamind Inc. (CSE:NM) (OTC PINK:NVMDF) ("Novamind" or "the Company"), a leading mental health company specialized in psychedelic medicine, is pleas...Read More
Novamind included as fast entry addition to the North American Psychedelics Index, the underlying index of the Horizons Psychedelic Stock Index ETFTORONTO, ON / ACCESSWIRE / February 22, 2021 / Novamind Inc. (CSE:NM | OTC PINK:NVMDF) ("Novamind" or "the Company"), a leadi...Read More
TORONTO, ON / ACCESSWIRE / February 19, 2021 / Novamind Inc., (CSE:NM)(OTC PINK:NVMDF) ("Novamind" or the "Company") a mental health company specialized in psychedelic medicine, announces that its common shares, previously listed for trading on the OTC Pink Market in the...Read More
Toronto, Ontario--(Newsfile Corp. - February 16, 2021) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of January 2021, which were highlighted by the highest monthly trading volume in the Exchange's history and a record amount of capit...Read More
Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD TreatmentTORONTO, ON / ACCESSWIRE / February 11, 2021 / Novamind Inc. (CSE:NM) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made...Read More
Conference highlights industry leaders and innovators in the psychedelic therapy space and features Michael Pollan, author of New York Times bestseller, "How to Change Your Mind"TORONTO, ON / ACCESSWIRE / January 29, 2021 / Novamind Inc. (CSE:NM) ("Novamind"), a mental he...Read More
Novamind's subsidiary Cedar Psychiatry has administered over 5,000 ketamine treatments and over 2,000 Spravato™ treatmentsTORONTO, ON / ACCESSWIRE / January 28, 2021 / Novamind Inc. (CSE:NM) ("Novamind"), a leading mental health company specialized in psychedelic medicine...Read More
TORONTO, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc., (ABXX:CN) (“Abaxx” or the “Company”), a financial software (fintech) company, majority shareholder of Abaxx Singapore Pte. Ltd., the Abaxx Commodity Exchange (ACX), and producer of the Smarter M...Read More
Features virtual presentations by eminent psychedelics companies and industry leadersTORONTO, ON / ACCESSWIRE / January 25, 2021 / Novamind Inc. (CSE:NM) ("Novamind" or the "Company"), a mental health company specialized in psychedelic medicine, today announced the Compan...Read More
TORONTO, ON / ACCESSWIRE / January 26, 2021 / Novamind Inc., (CSE:NM) ("Novamind" or the "Company") a mental health company specialized in psychedelic medicine, announces that is has entered into marketing services agreements with Octagon Media Corp. ("Octagon")...Read More
Pierre Bou-Mansour is former COO of LifeLabs, one of Canada's largest medical service companies TORONTO, ON / ACCESSWIRE / January 19, 2021 / Novamind Inc., (CSE:NM) ("Novamind" or the "Company") a mental health company specialized in psychedelic medicine, announces t...Read More